Literature DB >> 12833470

Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus.

Mark E Sherman1, Susan S Devesa.   

Abstract

BACKGROUND: In the United States, incidence rates for malignant tumors of the uterine corpus are lower among blacks than among whites, whereas mortality rates are higher among blacks. Reasons for the higher level of mortality among blacks have been debated.
METHODS: Using data from the Surveillance, Epidemiology, and End Results program, the authors compared incidence rates by histopathologic type for malignant tumors of the uterine corpus (including uterus, not otherwise specified) during the period 1992-1998 among white Hispanic, black, and white non-Hispanic patients. The authors also compared cumulative relative survival rates for blacks and whites by histopathologic type and by other factors, and they calculated estimated type-specific mortality rates.
RESULTS: Overall incidence (per 100,000 woman-years) of corpus malignancy was significantly lower among white Hispanics (14.04; 95% confidence interval [CI], 13.39-14.72) and blacks (15.31; 95% CI, 14.61-16.04) compared with white non-Hispanics (23.43; 95% CI, 23.06-23.81). Compared with white non-Hispanics, blacks had significantly higher incidence rates of serous/clear cell carcinoma (rate ratio, 1.85; 95% CI, 1.61-2.12), carcinosarcoma (rate ratio, 2.33; 95% CI, 1.99-2.72), and sarcoma (rate ratio, 1.56; 95% CI, 1.31-1.86). Survival was worse for blacks than for whites in every histopathologic category and in 'usual' types of endometrial adenocarcinoma, stratified by stage, grade, and age. Rare aggressive tumor types accounted for 53% of mortality among blacks, compared with 36% among whites.
CONCLUSIONS: Less favorable outcomes for usual types of endometrial adenocarcinoma and for rare aggressive tumors contribute equally to the relatively high mortality due to corpus cancer among black women.

Entities:  

Mesh:

Year:  2003        PMID: 12833470     DOI: 10.1002/cncr.11484

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  50 in total

Review 1.  Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.

Authors:  Karim S El-Sahwi; Peter E Schwartz; Alessandro D Santin
Journal:  Expert Rev Anticancer Ther       Date:  2012-01       Impact factor: 4.512

2.  Endometrial stromal sarcoma presenting as large bleeding left upper quadrant mass.

Authors:  Gaya Spolverato; Elizabeth Montgomery; Ihab Kamel; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2015-10       Impact factor: 7.293

3.  A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?

Authors:  June Y Hou; Thomas C McAndrew; Gary L Goldberg; Kathleen Whitney; Shohreh Shahabi
Journal:  Reprod Sci       Date:  2013-09-10       Impact factor: 3.060

Review 4.  Racial and ethnic disparities in cancers of the uterine corpus.

Authors:  O W Stephanie Yap; Roland P Matthews
Journal:  J Natl Med Assoc       Date:  2006-12       Impact factor: 1.798

5.  Racial disparities in young women with endometrial cancer.

Authors:  Barenya Mukerji; Caitlin Baptiste; Ling Chen; Ana I Tergas; June Y Hou; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2018-01-05       Impact factor: 5.482

6.  The influence of comorbid conditions on racial disparities in endometrial cancer survival.

Authors:  Julie J Ruterbusch; Rouba Ali-Fehmi; Sara H Olson; Shawnita Sealy-Jefferson; Benjamin A Rybicki; Sharon Hensley-Alford; Mohamed A Elshaikh; Arthur R Gaba; Daniel Schultz; Adnan R Munkarah; Michele L Cote
Journal:  Am J Obstet Gynecol       Date:  2014-06-19       Impact factor: 8.661

Review 7.  Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.

Authors:  Yvonne Collins; Kevin Holcomb; Eloise Chapman-Davis; Dineo Khabele; John H Farley
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

8.  Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.

Authors:  Jieqiong Liu; Wen Jiang; Kai Mao; Yi An; Fengxi Su; Betty Y S Kim; Qiang Liu; Lisa K Jacobs
Journal:  Breast Cancer Res Treat       Date:  2015-03-13       Impact factor: 4.872

9.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

10.  Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

Authors:  Louise A Brinton; Ashley S Felix; D Scott McMeekin; William T Creasman; Mark E Sherman; David Mutch; David E Cohn; Joan L Walker; Richard G Moore; Levi S Downs; Robert A Soslow; Richard Zaino
Journal:  Gynecol Oncol       Date:  2013-02-26       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.